Free Trial
→ My prediction for December 8th (From Behind the Markets) (Ad)tc pixel Free VCNX Stock Alerts
NASDAQ:VCNX

Vaccinex (VCNX) Stock Price, News & Analysis

Vaccinex logo
$1.00 0.00 (0.00%)
As of 11/6/2026 03:05 PM Eastern
Compare

About Vaccinex Stock (NASDAQ:VCNX)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$0.96
▼
$1.00
50-Day Range
$0.70
▼
$1.15
52-Week Range
$0.31
▼
$1.50
Volume
806 shs
Average Volume
2,758 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vaccinex, Inc. is a biotechnology company focused on developing antibody-based therapies for cancer and neurodegenerative diseases. The company’s lead product candidate, pepinemab (also known as VX15/2503), is an investigational monoclonal antibody designed to inhibit semaphorin 4D, a signaling protein associated with immune suppression, tumor progression and inflammation.

Vaccinex has evaluated pepinemab in clinical studies involving conditions such as head and neck cancer, metastatic breast cancer, Huntington’s disease and Alzheimer’s disease. The company’s research programs are intended to use targeted immune modulation to improve the body’s response to tumors and potentially address disease processes in the central nervous system.

Founded in 2001 and headquartered in Rochester, New York, Vaccinex has advanced its programs through collaborations and clinical development activities in the United States and other regions. Maurice Zauderer, Ph.D., is the company’s president and chief executive officer. Vaccinex became a publicly traded company in 2018 and continues to focus on the development of its antibody platform and therapeutic candidates.

AI Generated. May Contain Errors.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VCNX Stock News Headlines

SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376451/34858/en/sema4d-blockade-reshapes-the-tumor-immune-environment-in-neoadjuvant-melanoma-study.html
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Why Iran May Only Be the First Move
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen. No cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
 |  Behind the Markets (Ad)
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
See More Headlines

VCNX Stock Analysis - Frequently Asked Questions

Vaccinex's stock was trading at $1.0755 at the beginning of 2026. Since then, VCNX shares have decreased by 7.0% and is now trading at $1.00.

Vaccinex, Inc. (NASDAQ:VCNX) released its earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating analysts' consensus estimates of ($60.90) by $25.20. The business had revenue of $50 thousand for the quarter.

Vaccinex's stock reverse split on Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Vaccinex (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Palantir Technologies (PLTR), NIO (NIO), Nikola (NKLAQ), SNDL (SNDL), Tesla (TSLA), Workhorse Group (WKHS) and SCYNEXIS (SCYX).

Company Calendar

Today
11/08/2026
Next Earnings (Estimated)
11/16/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VCNX
CIK
1205922
Web
www.vaccinex.com
Phone
(585) 271-2700
Fax
585-271-2765
Employees
25
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
($48.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.25 million
Net Margins
N/A
Pretax Margin
-4,787.89%
Return on Equity
N/A
Return on Assets
-383.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.77
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$388 thousand
Price / Sales
6.70
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.59) per share
Price / Book
-0.39

Miscellaneous

Outstanding Shares
2,600,000
Free Float
1,261,000
Market Cap
$2.60 million
Optionable
No Data
Beta
1.10

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:VCNX) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Tesla pays zero dividends but this new fund pays monthly
Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...
Investors Alley | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
The IRS loophole Trump fought to preserve for retirees
401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...
American Hartford Gold | Sponsoredtc pixel